Buy Recommendation for Lexaria Bioscience Based on Improved Safety Profile of DehydraTECH-semaglutideValuation and Risks. Our 12-month price target is derived from an estimated market value of the firm at $130M. This includes a discounted cash flow (DCF) analysis-based asset value of $130M for DehydraTECH-GLP-1, using a 15% discount rate and 2% terminal growth rate. We have conservatively excluded the cash position. Assigned probability of approval is 15%. Assuming 33M shares outstanding at the end of August 2026, this yields a value of approximately $4 per share.